Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes

Background There are few data on the role of lipid lowering in the primary prevention of coronary heart disease (CHD) in diabetic patients. This paper describes the design of a collaborative clinical trial between Diabetes UK, the NHS Research and Development Directorate and Pfizer UK, that addresses this question.

[1]  Daniel Steinberg,et al.  Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. , 1988, Archives of internal medicine.

[2]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[3]  T. Wilt,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[4]  Thomas A. Pearson.  Lipid-lowering therapy in low-risk patients. , 1998, JAMA.

[5]  P. McNamara,et al.  Morbidity and Mortality in Diabetics In the Framingham Population: Sixteen Year Follow-up Study , 1974, Diabetes.

[6]  D. Hunninghake,et al.  Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) , 1998, The American journal of cardiology.

[7]  E. Manzato,et al.  Lipoprotein Abnormalities in Well-Treated Type II Diabetic Patients , 1993, Diabetes Care.

[8]  D L McGee,et al.  Diabetes and Glucose Tolerance as Risk Factors for Cardiovascular Disease: The Framingham Study , 1979, Diabetes Care.

[9]  R. Peto,et al.  Clinical trial methodology , 1978, Nature.

[10]  S. Johansson,et al.  Long-Term Prognosis After Myocardial Infarction in Men with Diabetes , 1985, Diabetes.

[11]  M. Mcneely,et al.  Accurate micromethod for estimation of both medium- and long-chain fatty acids and triglycerides in fecal fat. , 1973, Clinical chemistry.

[12]  D. Betteridge,et al.  Lipids, Diabetes, and Vascular Disease: The Time to Act , 1989, Diabetic medicine : a journal of the British Diabetic Association.

[13]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[14]  A. Nicolaides,et al.  Cardiovascular Outcomes in Type 2 Diabetes: A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study , 1998, Diabetes Care.

[15]  A. Rotchford,et al.  Assessing diabetic control — reliability of methods available in resource poor settings , 2002, Diabetic medicine : a journal of the British Diabetic Association.

[16]  Diabetes Atherosclerosis Intervention Study Investigators.  Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study , 2001, The Lancet.

[17]  J. Armitage,et al.  Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials , 2000, Heart.

[18]  J. Skolbekken,et al.  Alternative definitions , 1998, BMJ.

[19]  J. Neaton,et al.  Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial , 1993, Diabetes Care.

[20]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[21]  L. Rydén,et al.  Mortality and morbidity during a five-year follow-up of diabetics with myocardial infarction. , 2009, Acta medica Scandinavica.

[22]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[23]  J. Levy,et al.  U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease , 1995, Diabetes.

[24]  L. Kuller,et al.  SERUM CHOLESTEROL, BLOOD PRESSURE, AND MORTALITY: IMPLICATIONS FROM A COHORT OF 361 662 MEN , 1986, The Lancet.

[25]  M. Laakso,et al.  Retinopathy Predicts Coronary Heart Disease Events in NIDDM Patients , 1996, Diabetes Care.

[26]  R. Holman,et al.  Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23) , 1998, BMJ.

[27]  B. Davis,et al.  Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. , 1998, Circulation.

[28]  B V Howard,et al.  Dietary guidelines for healthy American adults. A statement for health professionals from the Nutrition Committee, American Heart Association. , 1996, Circulation.

[29]  J. Isaacsohn,et al.  Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. , 1996, JAMA.

[30]  M. Laakso,et al.  Lipids and Lipoproteins Predicting Coronary Heart Disease Mortality and Morbidity in Patients With Non-insulin-dependent Diabetes , 1993 .

[31]  M. Hanefeld,et al.  Diabetes Intervention Study: Multi-Intervention Trial in Newly Diagnosed NIDDM , 1991, Diabetes Care.

[32]  J. Fuller,et al.  International variations in cardiovascular mortality associated with diabetes mellitus: the WHO Multinational Study of Vascular Disease in Diabetes. , 1996, Annals of medicine.

[33]  S. Kenny,et al.  Proteinuria and Mortality in Diabetes: the WHO Multinational Study of Vascular Disease in Diabetes , 1995, Diabetic medicine : a journal of the British Diabetic Association.

[34]  Terje R Pedersen,et al.  Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) , 1997, Diabetes Care.

[35]  J. Mckenney,et al.  Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) , 1993, JAMA.

[36]  L. Niskanen,et al.  Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in Type 2 (non-insulin-dependent) diabetic and non-diabetic subjects , 1993, Diabetologia.